Filing Details
- Accession Number:
- 0001104659-17-056610
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-09-11 19:22:57
- Reporting Period:
- 2017-09-07
- Accepted Time:
- 2017-09-11 19:22:57
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1356576 | Supernus Pharmaceuticals Inc | SUPN | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1557657 | K.f. Stefan Schwabe | C/O Supernus Pharmaceuticals, Inc. 1550 East Gude Drive Rockville MD 20850 | Executive Vice President R&D | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2017-09-07 | 95,000 | $12.92 | 96,855 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2017-09-07 | 95,000 | $46.59 | 1,855 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Employee Stock Option (Right to Buy) | Disposition | 2017-09-07 | 95,000 | $0.00 | 95,000 | $12.92 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2022-08-09 | No | 4 | M | Direct |
Footnotes
- Transaction made pursuant to a Rule 10b5-1 trading plan adopted August 8, 2017.
- Includes an aggregate of 324 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan subsequent to the date of the Reporting Person's most recent filing on Form 4.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.000 to $47.800, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
- The option became exercisable in four equal installments beginning on August 9, 2013, which was the first anniversary of the date on which the option was granted.
Billionaire Hedge Funds
